Dr Garth Rapeport, CEO

Garth Rapeport is CEO of Pulmocide Ltd (http://pulmocide.com/), a drug discovery company working on the identification of new treatments for Invasive Aspergillosis and RSV and visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London.

Garth is a medical graduate who undertook post-graduate training in General Medicine and Clinical Pharmacology at the Universities of Glasgow and Oxford. He joined Pfizer Central Research in 1988 and was involved in the early development of range of new compounds. After moving to GSK he was head of the Respiratory Centre of Excellence for Drug Discovery (CEDD) leading to the development of new long acting inhaled therapies for COPD and asthma.

In 2006 he co-founded Respivert which was based at the Imperial College BioIncubator in London. Respivert was acquired by Centocor Ortho Biotech, a division of Johnson and Johnson in June 2010. In 2013.

Dr Pete Strong, CSO

Pete is Pulmocide’s Chief Scientific Officer. The majority of Pete’s pharmaceutical industry career between 1980 and 2003 was spent at Glaxo PLC, GlaxoWellcome and GlaxoSmithKline with a focus on respiratory drug discovery and development. Pete co-foundedr Respivert with Garth Rapeport and colleagues in 2007. Following the acquisition in 2010 by Centocor Ortho Biotech, Pete was a member of the small team which licensed the appropriate Respivert intellectual property rights to Topivert Ltd, leading to the successful Series A funding of that company.

Dr Alison Murray, Chief Medical Officer

Dr Alison Murray  is a medical virologist with extensive experience in the clinical development of medicines and molecular diagnostics for infectious diseases, having worked previously at The Wellcome Foundation, GlaxoWellcome, Gilead Sciences, Roche Molecular Systems and GSK.

Dr Kaz Ito, Director of Biology

Dr Kaz Ito is former Director of Biology at Respivert with an international reputation in COPD and asthma disease research.

Dr John Murray, Director of Medicinal Chemistry

Dr John Murray was Director of Medicinal Chemistry at Respivert with an extensive record of success at OSI pharmaceuticals and Glaxo Inc.

Dr Lindsey Cass, Director of Clinical Development

Dr Lindsey Cass was previously Director, Clinical Development at Respivert and GSK and has extensive experience in the Early Phase Clinical Development of inhaled molecules.

Dr Amanda Davis, Project Director

Dr Amanda Davis was previously Director of Project Management at Respivert and GSK.